Cipher Pharmaceuticals Inc
PHE
Company Profile
Business description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.
Contact
5750 Explorer Drive
Suite 404
MississaugaONL4W 0A9
CANT: +1 905 602-5840
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,118.00 | 39.70 | -0.43% |
| CAC 40 | 8,103.84 | 290.48 | -3.46% |
| DAX 40 | 23,753.02 | 884.98 | -3.59% |
| Dow JONES (US) | 48,561.44 | 343.34 | -0.70% |
| FTSE 100 | 10,452.50 | 327.61 | -3.04% |
| HKSE | 25,268.02 | 500.06 | -1.94% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 54,592.39 | 1,686.66 | -3.00% |
| NZX 50 Index | 13,534.03 | 122.62 | -0.90% |
| S&P 500 | 6,827.79 | 53.83 | -0.78% |
| S&P/ASX 200 | 8,899.20 | 37.80 | -0.42% |
| SSE Composite Index | 4,083.74 | 38.94 | -0.94% |